Side-by-side · Research reference
LivagenvsTriptorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/32 cited
BFDA-ApprovedHUMAN-REVIEWED16/64 cited
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
01Mechanism of Action
Parameter
Livagen
Triptorelin
Primary target
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Pituitary GnRH receptorsUnknown 2012
Pathway
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression
Downstream effect
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare
Feedback intact?
—
No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression
Origin
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability
Antibody development
—
—
02Dosage Protocols
Parameter
Livagen
Triptorelin
Animal dose (oral)
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
—
Duration (experimental)
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
—
Route
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
—
Evidence basis
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Multiple Phase 3 RCTs · FDA-approved 1999
Human data
None in provided literature
—
1-month depot
—
3.75 mg IM
Most common formulation for prostate cancer.
6-month depot
—
Administration route
—
Intramuscular (IM) — gluteal or deltoid
Frequency
—
Every 1, 3, or 6 months per formulation
Indication: Prostate cancer
—
Advanced (metastatic or locally advanced)
Androgen deprivation therapy (ADT) backbone.
Indication: Endometriosis
—
3.75 mg monthly
FDA-approved; typically 6-month course.
Indication: Central precocious puberty
—
Pediatric use (≥2 years)Jia 2025
Weight-based dosing per FDA label.
Duration (prostate cancer)
—
Continuous or intermittent ADT protocolsPreston 2024
Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.
Monitoring
—
Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose
04Side Effects & Safety
Parameter
Livagen
Triptorelin
Reported adverse effects
None documented in animal studies
—
Human safety data
No human trials in provided literature
—
Initial flare symptoms
—
Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)
Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.
Cardiovascular events
—
MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025Preston 2024
Hot flashes
—
Very common (>60%); vasomotor instability
Bone loss / Osteoporosis
—
Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025
Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.
Metabolic syndrome
—
Weight gain, insulin resistance, dyslipidemia, diabetes risk
Injection site reactions
—
Pain, erythema, sterile abscess (rare with depot formulations)
Gynecomastia / Breast tenderness
—
Common (10–20%); peripheral aromatization of residual androgens
Fatigue / Mood changes
—
Anemia, depression, cognitive changes reported in long-term ADT
Hepatotoxicity
—
Transient transaminase elevations; clinically apparent liver injury rare
Racial differences (ADT)
—
Black veterans show higher CV event rates vs White veterans on GnRH agonists
Absolute Contraindications
Livagen
—Triptorelin
- ·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
- ·Pregnancy (Category X)
Relative Contraindications
Livagen
—Triptorelin
- ·Active cardiovascular disease — consider GnRH antagonist alternative
- ·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
- ·Severe urinary obstruction — may worsen during flare
- ·Osteoporosis or high fracture risk (requires bone-protective therapy)
05Administration Protocol
Parameter
Livagen
Triptorelin
1. Route selection
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.
2. Timing
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.
3. Age-dependent response
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005
For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.
4. Monitoring schedule
—
Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.
5. Storage
—
Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.
6. Intermittent ADT protocol (optional)
—
Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.